Search results
Showing 211 to 225 of 264 results for carcinoma
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)
This guidance has been replaced by NICE technology appraisal guidance 474.
Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)
This guidance has been updated and replaced by NICE technology appraisal guidance 555.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Discontinued Reference number: GID-TA11005
High dose rate brachytherapy for carcinoma of the cervix (IPG160)
We have moved interventional procedures guidance 160 to become HealthTech guidance 104. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Selective internal radiation therapy for primary hepatocellular carcinoma (IPG460)
Interventional procedures, IPG460 - Issued: July 2013 --> We have moved interventional procedures guidance 460 to become HealthTech guidance 314. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued Reference number: GID-TA11421